Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis

Diabetes, Obesity and Metabolism

Volumn 16, Issue 1, 2014, Pages 30-37

  Wu, D ^a   Li, L ^a   Liu, C ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Linagliptin; Meta analysis; Metformin; Saxagliptin; Sitagliptin; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ARTICLE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT DURATION; WEIGHT CHANGE;

DIPEPTIDYL PEPTIDASE-4 INHIBITORS; LINAGLIPTIN; META-ANALYSIS; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; TYPE 2 DIABETES MELLITUS; VILDAGLIPTIN;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84890568491     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12174     Document Type: Article

References (47)

1. International Diabetes Federation (IDF). The Global Burden. [Online] Available from URL: http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed 3 April 2013.
2. Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol 2000; 7: 625-631.
3. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
4. Gerich J. Dpp-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010; 90: 131-140.
5. Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Drugs Today (Barc) 2007; 43: 801-814.
6. Gupta R, Walunj SS, Tokala RK et al. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets 2009; 10: 71-87.
7. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
8. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001; 20: 641-654.
9. Pfützner A, Paz-Pacheco E, Allen E et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76weeks. Diabetes Obes Metab 2011; 13: 567-576.
10. Aschner P, Katzeff HL, Guo H et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 252-261.
11. Williams-Herman D, Johnson J, Teng R et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2years in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 442-451.
12. Reasner C, Olansky L, Seck TL et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 644-652.
13. Bosi E, Dotta F, Jia Y et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 506-515.
14. Schweizer A, Couturier A, Foley JE et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1year in drug-naïve patients with type 2 diabetes. Diabet Med 2007; 24: 955-961.
15. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, doubleblind, randomized trial. Diabetes Obes Metab 2009; 11: 804-812.
16. Haak T, Meinicke T, Jones R et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012; 14: 565-574.
17. Rosenstock J, Aguilar-Salinas C, Klein E et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009; 25: 2401-2411.
18. Jadzinsky M, Pfützner A, Paz-Pacheco E et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-622.
19. Goldstein BJ, Feinglos MN, Lunceford JK et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987.
20. Williams-Herman D, Johnson J, Teng R et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569-583.
21. Scheen AJ. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Expert Opin Drug Metab Toxicol 2013; 9: 363-377.
22. Ahrén B. Novel combination treatment of type 2 diabetes DPP-4 inhibition+metformin. Vasc Health Risk Manag 2008; 4: 383-394.
23. Haak T. Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia. Adv Ther 2012; 29: 1005-1015.
24. Bosi E, Camisasca RP, Collober C et al. Effects of vildagliptin on glucose control over 24weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.
25. Nauck MA, Ellis GC, Fleck RP et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63: 46-55.
26. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009; 41: 368-373.
27. Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diabetes 2010; 15: 19-26.
28. Forst T, Uhlig-Laske B, Ring A et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 2010; 27: 1409-1419.
29. Yang W, Pan CY, Tou C et al. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 2011; 94: 217-224.
30. Taskinen MR, Rosenstock J, Tamminen I et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
31. Yang W, Guan Y, Shentu Y et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes 2012; 4: 227-237.
32. Barnett AH. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag 2009; 5: 141-151.
33. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358: 2630-2633.
34. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008; 359: 1092-1095.
35. Frederich R, Alexander JH, Fiedorek FT et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122: 16-27.
36. Williams-Herman D, Engel SS, Round E et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10, 246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: 7.
37. Johansen OE, Neubacher D, von Eynatten M et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11: 3.
38. White WB, Bakris GL, Bergenstal RM et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 2011; 162: 620-626.
39. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013; 10: 73-84.
40. Patil HR, Al Badarin FJ, Al Shami HA et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012; 110: 826-833.
41. Rosenstock J. Management of type 2 diabetes in the elderly: special considerations. Drugs Aging 2001; 18: 31-44.
42. Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010; 8: 405-418.
43. Paolisso G, Monami M, Marfella R et al. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Adv Ther 2012; 29: 218-233.
44. Pratley RE, Rosenstock J, Pi-Sunyer FX et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007; 30: 3017-3022.
45. Schweizer A, Dejager S, Foley JE et al. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011; 13: 55-64.
46. Doucet J, Chacra A, Maheux P et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011; 27: 863-869.
47. Pratley RE, Kipnes MS, Fleck PR et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11: 167-176.